Discussion
The U.S. Food and Drug Administration has approved the anti-CD20 therapy Revlimid (lenalidomide) as a maintenance therapy for multiple myeloma patients who received an…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Discussion
Discussion
Multiple myeloma (MM) patients treated at facilities that handle more patients may have better survival rates than those treated at lower-volume facilities, according to recent…
Discussion
The first multiple myeloma patient has enrolled in a trial of Celyad‘s T-cell therapy for seven types of cancer that have failed to respond to treatment.
Discussion
A man who calls himself a Hollyweed artist has started an Indiegogo crowdfunding campaign to create T-shirts marking California’s legalization of recreational marijuana — and…
Discussion
Patients with smoldering multiple myeloma (SMM), an asymptomatic form of myeloma, do not benefit from treatment with the anti-ICAM1 antibody BI-505, according to the results…
Discussion
A Phase 1 trial will soon be assessing Actimab-M, an anti-CD33 antibody bound to a radioactive compound, in heavily treated multiple myeloma patients, the compound’s developer,…
